US States Withdraw Medicaid Coverage for Weight-Loss Drugs as Costs Skyrocket
Faced with unsustainable expenditure increases, numerous American states and cities have begun restricting or eliminating Medicaid coverage for GLP-1 weight-loss medications such as Ozempic and Wegovy. This policy shift directly impacts low-income residents and public employees who previously benefited from public funding for these treatments.
Financial Pressures Force Coverage Restrictions
The decision stems from a dramatic surge in public spending on these pharmaceuticals. National expenditure on GLP-1 drugs ballooned from $13.7 billion in 2018 to $71.7 billion in 2023, representing a staggering 500 percent increase according to data published in the Journal of the American Medical Association.
By January of this year, several states had implemented significant restrictions:
- California, New Hampshire, Pennsylvania, and South Carolina terminated Medicaid coverage for weight-loss indications
- Michigan limited coverage exclusively to individuals classified as morbidly obese (BMI above 40)
- Rhode Island's governor proposed ending coverage entirely
Major urban centers are following suit. New York City's health insurer ceased covering GLP-1 drugs for municipal employees in 2025, while Boston officials are considering similar limitations due to insurance rate hikes primarily driven by medication costs.
Healthcare Professionals Warn of Long-Term Consequences
Medical experts argue that while these cuts may provide short-term budgetary relief, they will ultimately exacerbate long-term healthcare costs related to obesity complications. Dr. Matthew Klebanoff, a professor of internal medicine at the Perelman School of Medicine, emphasized the dilemma facing policymakers.
"Patients should have access to these therapies," Klebanoff stated. "It's just very challenging right now for payers to be able to afford covering these medications for everyone who could benefit."
The obesity rate among American adults reached 40 percent in August 2023 according to Centers for Disease Control and Prevention data. While GLP-1 drugs contributed to reducing this rate to 37 percent by 2025, maintaining this progress has proven financially burdensome for public health programs.
Personal Impact and Legislative Responses
The policy changes have tangible consequences for individuals like Alexa Canciello, a 23-year-old Medicaid recipient with autism who lives near Pittsburgh. After losing nearly 30 pounds using Zepbound, her coverage was terminated in January, forcing her onto a less effective alternative medication.
"There are a lot of people out there that could probably lose weight without GLP-1 drugs if they just discipline themselves and exercise more," said her father Rich Canciello. "But there is a segment of the population that cannot lose weight, and my daughter Alexa unfortunately falls within that category."
Pennsylvania State Representative Arvind Venkat, a physician, has introduced legislation proposing a subscription-based model for GLP-1 drugs, similar to Louisiana's 2019 "Netflix model" agreement for hepatitis C medications. This approach would involve value-based arrangements with pharmaceutical manufacturers through supplemental rebate agreements.
"If all we are trying to accomplish is to save money on a single year budget basis, the state is doing that," Venkat argued. "But our goal should be more than that. It should be to keep people healthy."
Broader Context and Future Outlook
Sixteen state Medicaid programs continued covering GLP-1 drugs for obesity as of October 2025, though most states maintain coverage for diabetes indications. The financial strain is compounded by the impending reduction of $665 billion in state Medicaid funding over the next decade under legislation associated with the previous administration.
Pennsylvania's experience illustrates the scale of the challenge. Medicaid spending on GLP-1 drugs in the state reached $1.3 billion in 2025, doubling from the previous year. State officials cited an "unsustainable rise in costs" as justification for implementing stricter eligibility criteria.
Dr. Klebanoff remains optimistic that market competition will eventually drive down prices, drawing parallels with the hepatitis C treatment market in the 2010s. In the interim, he anticipates more Medicaid recipients may pursue sleep studies to qualify for coverage through sleep apnea diagnoses.
The fundamental tension between immediate budgetary constraints and long-term public health investment continues to shape policy decisions across American states, with significant implications for vulnerable populations dependent on Medicaid coverage.
